Tumor suppressor genes and breast cancer

Radiation Oncology Investigations

Volumn 7, Issue 2, 1999, Pages 55-65

  Buchholz, Thomas A ^a   Weil, Michael M ^a   Story, Michael D ^a   Strom, Eric A ^a   Brock, William A ^a   McNeese, Marsha D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ATM; BRCA1; BRCA2; Breast cancer; p53

Indexed keywords

DNA; PROTEIN P53;

ATAXIA TELANGIECTASIA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; DNA DAMAGE; DNA REPAIR; FEMALE; GENE MUTATION; GENETIC STABILITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR CLONING; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0032910431     PISSN: 10657541     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1520-6823(1999)7:2<55::aid-roi1>3.0.co;2-%23     Document Type: Review

References (76)

1. Kinzler KW, Voleglstein B. Gatekeepers and caretakers. Nature 1997;386:761-764.
2. Harris CC. The 1995 Walter Hubert Lecture-molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1995;73:261-269.
3. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. Nature Med 1997;3:721-722.
4. Kaston MB, Zahn QM, Eldeiry WS, Carrier F, Jacks T, Walsh WY, Plunkett BS, Vogelstein B, Fornace A. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-597.
5. Baskaran R, Wood LD, Whitaker LL, Canman CE, Morgan SE, Xu Y, Barlow C, Baltimore C, Wynshaw-Boris A, Kastan MB, Wang JYJ. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature 1997;387:516-519.
6. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122:135-140.
7. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;24:1879-1886.
8. Lynch HT, Guirgis HA, Albert S, Brennan M, Lynch J, Kraft C, Pocekay D, Vaughns C, Kaplan A. Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 1974;138(5):717-724.
9. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King M-C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 1998;279:915-921.
10. Ford D, Easton DF. The genetics of breast and ovarian cancer. Br J Cancer 1995;72:805-812.
11. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1997;253:49-53.
12. Greenblatt MS, Grollman AP, Harris CC. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/ misalignment model. Cancer Res 1996;56:2130-2136.
13. Malkin D, Li FP, Strong LC, Fraumeni, Jr JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-1238.
14. Li FP. Familial cancer syndromes and clusters. Curr Probl Cancer 1990;14:73-144.
15. Velculescu V, El-Deiry WS. Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 1996;42(6):858-868.
16. Donehower LA. The p53-deficient mouse: a model for basic and applied cancer studies. Sem Cancer Bio 1996; 7:269-278.
17. Bischoff FZ, Yim SO, Pathak S, Grant G, Siciliano MJ, Giovanella BC, Strong LC, Tainsky MA. Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. Cancer Res 1990;50:7979-7984.
18. Wazer DE, Chu Q, Liu XL, Gao Q, Safaii H, Band V. Loss of p53 protein during radiation transformation of primary human mammary epithelial cells. Mol Cell Biol 1994;14:2468-2478.
19. Gao Q, Hauser SH, Liu XL, Wazer DE, Madoc-Jones H, Band V. Mutant p53-induced immortalization of primary human mammary epithelial cells. Cancer Res 1996;56:3129-3133.
20. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine J. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8:531-539.
21. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ. Gain of function mutations in p532. Nature Genet 1993;4:42-46.
22. Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proc Natl Acad Sci 1998;95:5166-5171.
23. Vogelstien B, Kinzler KW. p53 function and dysfunction. Cell 1997;70:523-526.
24. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-6311.
25. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377: 552-557.
26. Meyn RE, Stephens LC, Mason KA, Medina D. Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Int J Cancer 1996;65:466-472.
27. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Hoffman B, Liberman D, Reed JC. Tumor suppressor p53 is a regulator of blc-2 and bax in gene expression in vitro and in vivo. Oncogene 1994;9: 1799-1805.
28. Meyn RE, Stephens LC, Hunter NR, Milas L. Apoptosis in murine tumors treated with chemotherapy agents. Anti-Cancer Drugs 1995;6:443-450.
29. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 1996;88(18).
30. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 1995; 35:297-303.
31. Kovach JS, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer SS. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc Natl Acad Sci USA 1996;93(3):1093-1096.
32. Stal O, Stenmark AM, Wingren S, Rutqvist LE, Skoog L, Ferraud L, Sullivan S, Carstensen J, Nordenskjold B. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol 1995;34(6):767-70.
33. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: An immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995;13:821-830.
34. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-855.
35. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
36. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250:1684-1689.
37. Wooster R, Neuhausen SL, Mangion J, Quirk U, Ford D, Collinz N, Nguyen K, Seal S, Tran T, Averill C, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378,789-792.
38. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336(20):1401-1408.
39. Boyd M, Harris F, McFarlane R, Davidson HR, Black DM. A human BRCA1 gene knockout. Nature 1995; 375:541-542.
40. Wang SC, Lin SH, Su LK, Hung MC. Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 1997;234:247-251.
41. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, Iglehart JD. Cell cycle control of BRCA2. Cancer Res 1996;56:4590-4594.
42. Gudas JM, Nguyen H, Lit T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 1995;55:4561-4565.
43. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA. BRCA1 Required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012.
44. Sharan SK, Wilms M, Bradley A. Murine Brca1: sequence and significance for human missense mutations. Hum Mol Genet 1995;4:2275-2278.
45. Hakem R, de la Pampa JL, Sirard C, Mo R, Woo M, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billa F, Firpo E, Hui CC, Roberts J, Rossant J, Mak TW. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 1996;85(7):1009-1023.
46. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P, Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 1997; 386:804-810.
47. Ludwig T. Chapman DL. Papaioannou VE. Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes & Development 1997;11(10): 1226-1241.
48. Scully R, Chen J, Plug A, Xiao U, Weaver D, Feunteun J, Ashley T, Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997;88: 265-275.
49. Lim DS. Hasty P. A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p532. Mol Cell Biol 1996;16:7133-7143.
50. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-1510.
51. Robson M, Rajan P, Rosen PP, Gilewski T, Hirschaut Y, Pressman P, Haas B, Norton L, Offit K. BRCA-associated breast cancer: absence of a characteristic immunophenotype. Cancer Res 1998;58:1839-1842.
52. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, Vincent-Salomon A, Jacquemier J, Birnbaum D, Sobol H. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4743.
53. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. J Clin Oncol 1996;14: 1730-1736.
54. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH-F, Adey N et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. JAMA 1997;278:1242-1250.
55. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salemo G, Conway TA, Lynch HT. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
56. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994;266: 120-124.
57. Verhoog LC, Brekelmans CTM, Seynaeve C, van den Bosch LMC, Dahmen G, van Geel AN et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998;351: 316-321.
58. Gaffney DK, Brohert RM, Lewis CM, Holden JA, Buys SS, Neuhausen SL, Steele L, Avizonis V, Stewart JR, Cannon-Albright LA. Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations. Radiother Oncol 1998;47:129-136.
59. Boder E, Sedgwick RP. Ataxia-telangiectasia. A familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. A preliminary report of 7 children, an autopsy, and a case history. Univ Sth Calif Med Bull 1957;9:15-28.
60. Shiloh Y, Rotman G. Ataxia-telangiectasia and the ATM gene: linking nuerodegeneration, immunodefeciency, and cancer to cell cycle checkpoints. J Clin Immunol 1996;16:254-260.
61. Peterson RDA, Kelly WD, Good RA. Ataxia-telangiectasia: its association with a defective thymus, immunological-deficiency disease, and malignancy. Lancet 1964;1:1189-1193.
62. Pippard EC, Hall AJ, Barker DJ, Bridges BA. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res 1988;48:2929-2932.
63. Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the U.S. Am J Hum Genet 1986;39:573-583.
64. Swift M, Peitnauer P, Morrell D, Chase C. Breast and other cancers in families with ataxia telangiectasia. N Engl J Med 1987;316:1289-1294.
65. Swift M, Morrell D, Massey R, Chase C. Incidence of cancers in 161 families affected by ataxia telangiectasia. N Engl J Med 1991;325:1831-1836.
66. FitzGerald MG, Bean JM, Hegde SR, Unsal H, McDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nature Genet 1997;15:307-310.
67. Vorechovsky, I., Rasio, D., Luo, L., Monaco, C., Hammarstrom, A., Webster, A.D.B., Zaloudik, J., Barbanti-Brodano, G., James, M., Russo, G., Croce, C., Negrini, M. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res 1996;56:2726-2732.
68. Athma P Rappaport R, Swift M. Molecular genotyping show that ataxia telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 1996;92:130-134.
69. Cunliffe PN, Mann JR, Cameron AH, Roberts KD. Radiosensitivity in ataxia-telangiectasia. Br J Radiol 1975;48:374-376.
70. Hall E. Cell-survival curves. In: Hall E, editor. Radiobiology for the radiologist. Third edition. Philadelphia: Lippincott; 1988. p 17-38.
71. Kinsella TJ, Mitchell JB, McPherson S, Russo A, Tietze F. In vitro X-ray sensitivity in ataxia-telangiectasia homozygote and heterozygote skin fibroblasts under oxic and hypoxic conditions. Cancer Res 1982;42: 3950-3956.
72. Weeks DE, Paterson MC, Lange K, Andrais B, Davis RC, Yoder F, Gatti RA. Assessment of chronic γ radiosensitivity as an in vitro assay for heterozygote identification of ataxia-telangiectasia. Rad Res 1991;128: 90-99.
73. Blocher D, Sigut D, Hannan MA. Fibroblasts for ataxia telangiectasia (AT) and AT heterozygotes show an enhanced level of residual DNA double-strand breaks after low dose-rate γ-irradiation as assayed by pulsed field gel electrophoresis. Int J Radiat Biol 1991;60: 791-802.
74. Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatel M Zhang N, Watter D, Egerton M, Siloh Y, Kharbanda S, Kufe D, Lavin MF. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997;387:520-523.
75. Kharbanda S, Pandey P, Jin S, Inoue S Bharti A, Yuan ZM, Weichselbaum R, Weaver D, Kufe D. Functional interaction between DNA-PK and c-Able in response to DNA damage. Nature 1997;386:732-735.
76. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE, Lee, PWK. DNA-dependent protein kinase acts upsteam of p53 in response to DNA damage. Nature 1998; 394:700-704.